Table 2.
Immunogenicity at baseline, 14- and 28-days post second dose (rAd25, ChAdOx1 or BBIBP-CorV).
| Vaccine schedule | Day |
Geometric mean concentration day 28–0 | ||
|---|---|---|---|---|
| 0 | 14 | 28 | ||
| Geometric mean (GM) anti-S titres (IU/mL) | ||||
| rAd26/rAd5 | 46.1 | 417.0 | 543.6 | 11.78 (7.05–19.67) |
| rAd26/ChAdOx1 | 128.9 | 670.0 | 619.7 | 4.81 (2.14–10.81) |
| rAd26/BBIBP-CorV | 63.5 | 101.3 | 97.5 | 1.53 (0.74–3.20) |
| GMC ratioa | ||||
| rAd26/rAd5 | 1.00 | 1.00 | 1.00 | |
| rAd26/ChAdOx1 | 2.79 (1.30–6.03) | 1.61 (0.94–2.74) | 1.14 (0.69–1.88) | |
| rAd26/BBIBP-CorV | 1.38 (0.70–2.72) | 0.24 (0.14–0.42) | 0.18 (0.11–0.30) | |
| No. of participants | ||||
| rAd26/rAd5 | 31 | 30 | 27 | |
| rAd26/ChAdOx1 | 24 | 24 | 26 | |
| rAd26/BBIBP-CorV | 27 | 27 | 22 | |
a
GMC ratio was calculated as the antilogarithm of the difference between the mean of the log10 transformed SARS-CoV-2 anti-spike IgG in the heterologous groups and that in rAd26/rAd5 (as reference category).